Revolution Medicines Inc is driven by a strong set of values and corporate philosophy. The company is dedicated to transforming patient lives by targeting frontier targets within notorious cancer-promoting pathways. Revolution Medicines utilizes a precision oncology approach to create innovative therapies that selectively inhibit drivers of cancerous growth. Their research and development efforts focus on identifying vulnerabilities in cancer cells, leading to the discovery of potential breakthrough treatments. By collaborating with academic institutions and industry leaders, Revolution Medicines is committed to advancing scientific knowledge and delivering novel therapies to patients in need. With their patient-centric approach and commitment to scientific excellence, Revolution Medicines Inc aims to revolutionize the field of oncology.

Revolution Medicines Inc is primarily present in the United States.

Revolution Medicines Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2020, raising substantial funds for its innovative drug discovery and development programs. Revolution Medicines Inc also received the Breakthrough Therapy Designation from the U.S. FDA for its targeted therapy, RMC-4630, in 2021. This designation highlights the potential of RMC-4630 to address unmet medical needs in patients with specific cancer mutations. Additionally, the company has forged several strategic collaborations with renowned institutions and pharmaceutical companies, further validating its pioneering approach towards precision medicine. Revolution Medicines Inc's milestone achievements reflect its commitment to advancing patient care through novel therapies and collaborations within the pharmaceutical industry.

Revolution Medicines Inc. is a leading biopharmaceutical company focused on developing innovative precision therapies targeting frontier oncology targets. Founded in 2014, Revolution Medicines aims to address the unmet needs of patients with genomically defined cancers. The company utilizes a proprietary drug discovery platform, called the Restricted Pharmacophoric Space (RPS), to systematically explore the vastness of chemical space. This approach enables the identification of novel small molecule modulators for challenging, yet high-value, cancer targets. Revolution Medicines leverages its expertise and strategic partnerships to advance its pipeline, with the ultimate goal of transforming the lives of patients through the discovery and development of transformative medicines.

The main competitors of Revolution Medicines Inc in the market include companies such as Mirati Therapeutics Inc, Turning Point Therapeutics Inc, Nektar Therapeutics, Blueprint Medicines Corporation, and Ideaya Biosciences Inc.

Revolution Medicines Inc is primarily active in the biotechnology and pharmaceutical industries. As a leading company in the field, Revolution Medicines focuses on discovering and developing innovative therapies for patients with serious diseases, including those with cancer. By using their proprietary drug discovery platform, the company aims to identify and target important pathways and drivers of diseases, transforming the lives of patients worldwide. Revolution Medicines Inc strives to make groundbreaking advancements in the biotech and pharmaceutical sectors to improve healthcare and contribute to the overall well-being of individuals.

Revolution Medicines Inc is a biotechnology company focused on discovering and developing new treatments for patients with cancer. Their business model is centered around the discovery and advancement of innovative, precision oncology therapies. By leveraging their expertise in targeted therapies, Revolution Medicines aims to develop breakthrough medicines that specifically target the underlying drivers of cancer. Through strategic collaborations and internal research and development efforts, the company aims to bring transformative treatments to patients in need. Revolution Medicines Inc is committed to advancing the field of precision oncology and making a meaningful impact on patients' lives.

Коефициентът на цена спрямо печалбата (КЦП) на Revolution Medicines е -10,94.

Коефициентът на цена към оборот (KUV) на Revolution Medicines е 19 965,07.

AlleAktien качественият резултат за Revolution Medicines е 2/10.

очаквана Revolution Medicines оборотът е 327 858,60 USD.

очаквана Revolution Medicines печалба е -598,34 млн. USD.

Revolution Medicines Inc is a biotechnology company focused on researching and developing cancer drugs. Their business model is based on identifying cancer cell-specific target molecules and developing drugs that specifically target these molecules. The company has developed a proprietary drug discovery platform that allows them to understand the structural complexity of cancer cells as well as their metabolic pathways, and identify specific targets for new drugs. The platform uses a combination of bioinformatics methods, chemistry, and genomics and has been used to develop drugs for serious types of cancer such as breast, colorectal, and lung cancer. Revolution Medicines' product portfolio includes a variety of drug candidates at different stages of preclinical and clinical development. Some of the most promising candidates are RMC-4630, RMC-5552, and RMC-5845, which are currently in Phase 1 and 2 clinical trials. RMC-4630 is an inhibitor for the KRAS oncogene, which is mutated in numerous cancer types but has been difficult to treat. RMC-5552 is a specific inhibitor of the SHP2 protein, which stimulates growth in many types of cancer. RMC-5845 blocks the activity of an enzyme called SHMT2, which may play a crucial role in cancer development. Revolution Medicines has also entered into a collaboration agreement with Sanofi to jointly develop new drugs based on its proprietary platform. Under the agreement, the company will receive up to $560 million in total, and both companies will share the profits generated. The company also has a promising pipeline of additional drug candidates currently in preclinical development, including inhibitors for other cancer-specific target molecules. Additionally, the company has developed a spin-off platform called Revolution AgRx, which uses similar approaches to develop new agricultural chemicals. In summary, Revolution Medicines' business model focuses on developing innovative drugs for the treatment of cancer. The company utilizes its proprietary drug discovery platform to identify specific target molecules and develop new drugs that target these molecules. Revolution Medicines has a wide range of drug candidates at different stages of development and has a collaboration agreement with Sanofi to jointly develop new drugs.

Revolution Medicines разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Revolution Medicines в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Revolution Medicines е US76155X1000.

WKN на Revolution Medicines е A2PYWG.

Тикерът на Revolution Medicines е RVMD.

През последните 12 месеца Revolution Medicines изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Revolution Medicines да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Revolution Medicines в момента е .

Revolution Medicines изплаща дивидент на тримесечие. Той се разпределя в месеците .

Revolution Medicines платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Revolution Medicines се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Revolution Medicines на 30.11.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 30.11.2024 г..

Последното дивидентно плащане беше извършено на 30.11.2024 г..

През година 2023 Revolution Medicines изплати 0 USD под формата на дивиденти.

Дивидентите от Revolution Medicines се изплащат в USD.